KROSHealthcare · BiotechnologyThe 7 Wall Street analysts covering Keros Therapeutics, Inc. hold a median 12-month price target of $19 — +63.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 8 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Keros Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KROS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +63.2% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Leerink Partners | Maintains | Outperform | $30 → $23 |
| 4 Aug 2026 | Wells Fargo | Maintains | Overweight | $20 → $18 |
| 5 Mar 2026 | Wells Fargo | Maintains | Overweight | $23 → $20 |
| 5 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 Nov 2025 | B of A Securities | Maintains | Neutral | — |
| 12 Nov 2025 | Oppenheimer | Reiterates | Outperform | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 6 Nov 2025 | Wedbush | Maintains | Neutral | — |
| 8 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2025 | B of A Securities | Downgrade | Neutral | — |
| 30 May 2025 | Wedbush | Reiterates | Neutral | — |
| 12 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 8 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Apr 2025 | Truist Securities | Maintains | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | Wedbush | Reiterates | Neutral | — |
| 27 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2025 | Wells Fargo | Maintains | Overweight | — |
| 21 Jan 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 17 Jan 2025 | Guggenheim | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KROS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Keros Therapeutics, Inc. returned −27.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 11% of US stocks
Cheaper than 76% of US stocks
Cheaper than 60% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
Higher than 32% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Keros Therapeutics, Inc. has a market value of $218.3M and an enterprise value of −$23.6M.
Revenue in the twelve months to 30 June 2026: $15.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$83.2M, a −553.9% net margin.
Diluted earnings per share, trailing twelve months: $−3.70.
Free cash flow in the twelve months to 30 June 2026: −$48.5M.
Trailing P/E: 4.6×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Keros Therapeutics, Inc. employs 92 people — $163K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Keros Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Keros Therapeutics has begun dosing patients in a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD). Initial data from the trial are expected in the first half of 2027.
Why it matters — This milestone advances rinvatercept into a new clinical stage and provides KROS watchers with a clear upcoming catalyst in the DMD program.
Keros Therapeutics announced it expects to receive a $20 million development milestone payment from partner Takeda under the license agreement for elritercept, following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for myelofibrosis. The trial is a multicenter, double-blind, randomized study comparing elritercept to placebo in patients with myelofibrosis and anemia on concurrent ruxolitinib therapy.
Why it matters — A Keros watcher would care because the milestone payment reflects progress in the elritercept program and provides additional non-dilutive funding for the company.
Keros Therapeutics announced that the first patient has been dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (DMD). The trial is part of the company's efforts to develop novel therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.
Why it matters — This marks a clinical advancement for Keros' rinvatercept program, moving it into Phase 2 development for DMD, which is a key milestone for the company's pipeline.
Keros Therapeutics announced that its Board of Directors approved a $5 million share repurchase program for the company's common stock, authorizing management to repurchase shares from time to time in the open market or by other means in accordance with securities laws. The authorization follows receipt of a $20 million development milestone payment under the elritercept license agreement with Takeda Pharmaceuticals, triggered by the dosing of the first patient in the ELRiSE MDS clinical trial.
Why it matters — A KROS watcher would care because the repurchase program signals the company has unlocked milestone revenue from its Takeda partnership and is returning capital to shareholders.
Keros Therapeutics (KROS) reported earnings about 30 days ago, and the stock has risen 8% since that report. The item examines what may come next for the company's shares.
Why it matters — KROS watchers would care because the post-earnings price gain signals investor interest and raises the question of whether the momentum will continue going forward.
The 7 Wall Street analysts covering Keros Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Keros Therapeutics, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Keros Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Keros Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +63.2% from the last close, and Ticker Nerd's factor model ranks Keros Therapeutics, Inc. 71 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Keros Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KROS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.
Keros Therapeutics, Inc. returned -27.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins.
The most recent item we track (Zacks Investment Research, 29 Sept 2026): "KROS Begins Dosing in Phase II Study With Rinvatercept in DMD". Keros Therapeutics has begun dosing patients in a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD). Initial data from the trial are expected in the first half of 2027.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.
CEO Dr. Jasbir S. Seehra Ph.D. · 92 employees · United States · https://www.kerostx.com
